Business, energy, technology, markets and global industry news from Business News Today

Pharma & Biotech

PharmaDeviceNews Pharma & Biotech
Representative image of an oncology researcher reviewing bladder cancer treatment data, as ImmunityBio’s ANKTIVA plus BCG analysis raises new questions about cost, response durability and bladder-sparing care in BCG-unresponsive NMIBC.
Pharma & Biotech

Why ImmunityBio’s ANKTIVA cost analysis could intensify the bladder cancer value debate

Bladder cancer drugs face a value test. ImmunityBio’s ANKTIVA analysis raises new questions on cost, response durability and access.

Read More
Representative image: An oncology specialist reviews treatment information with a breast cancer patient in a clinical setting, reflecting Gilead Sciences’ Trodelvy regulatory progress in first-line metastatic triple-negative breast cancer care.
Pharma & Biotech

Gilead’s Trodelvy gains EU regulatory momentum, but the first-line TNBC fight is only beginning

Gilead’s Trodelvy may move earlier in metastatic TNBC. The EU signal could reshape first-line ADC use, but adoption questions remain.

Read More
Representative image: A clinician reviews bladder cancer imaging in a modern oncology setting, reflecting Merck’s KEYTRUDA plus Padcev EU regulatory milestone for cisplatin-ineligible muscle-invasive bladder cancer patients.
Pharma & Biotech

Why Merck’s CHMP win for KEYTRUDA plus Padcev matters in muscle-invasive bladder cancer

Merck’s bladder cancer push is moving earlier in Europe. KEYTRUDA plus Padcev could reset cisplatin-ineligible MIBC care.

Read More
Representative image: A hematology researcher reviews blood sample data in a clinical laboratory, reflecting PharmaEssentia’s new ropeginterferon alfa-2b evidence in essential thrombocythemia ahead of ASCO 2026 and EHA 2026.
Pharma & Biotech

Can PharmaEssentia turn ropeginterferon into a broader myeloproliferative neoplasm franchise?

PharmaEssentia’s ET data arrive before a key FDA date. Ropeginterferon could shift timing, sequencing, and risk thinking in MPN care.

Read More
Representative image: A cancer patient receives infusion-based oncology care in a modern clinic, reflecting Datroway’s FDA approval as a new first-line treatment option for metastatic triple-negative breast cancer patients who are not eligible for immunotherapy.
Pharma & Biotech

AstraZeneca and Daiichi Sankyo deepen ADC ambitions with Datroway’s TNBC approval

Datroway challenges chemotherapy in first-line TNBC. AstraZeneca and Daiichi Sankyo now face the real test: adoption, safety and access.

Read More
Representative image: A haematology consultation illustrates how PYRUKYND’s European Union approval for adults with thalassaemia could shift attention toward oral rare blood disease treatments, patient access and reimbursement across Europe.
Pharma & Biotech

Could Agios and Avanzanite turn PYRUKYND into Europe’s next rare blood disease launch test?

PYRUKYND has EU approval in thalassaemia. Now Agios and Avanzanite face Europe’s harder test: access, uptake and reimbursement.

Read More
Galderma wins FDA approval for Differin Epiduo OTC switch as acne treatment access expands
Pharma & Biotech

Why Galderma’s acne gel approval could quietly reset the over the counter dermatology market

Acne care is moving from prescription desks to retail shelves. Galderma’s Differin Epiduo switch tests how far OTC dermatology can go.

Read More
Pharma & Biotech

Why AstraZeneca’s EMERALD-3 and SERENA-6 data could influence future standards of cancer care

Could AstraZeneca’s latest ASCO 2026 cancer data reshape future treatment sequencing in liver and breast oncology? Read the full analysis.

Read More
Pharma & Biotech

How Gilead Sciences, Inc. could strengthen its liver disease franchise through Hepcludex commercialization

FDA approval of Hepcludex gives HDV its first U.S. therapy. Find out how this could reshape liver disease treatment and Gilead’s strategy.

Read More
Pharma & Biotech

Why Assembly Biosciences’ liver disease strategy now extends far beyond viral hepatitis

Assembly Biosciences is expanding ABI-6250 beyond HDV into PBC and PSC. Find out why NTCP inhibition is gaining industry attention.

Read More